43 results
8-K
EX-10.1
ORKA
Oruka Therapeutics Inc.
13 Sep 24
Oruka Therapeutics Announces $200 Million Private Placement
4:02pm
and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects and except to the extent any
425
ORKA
Oruka Therapeutics Inc.
9 Aug 24
Business combination disclosure
8:35am
have become effective with SEC (see “SEC Filings” below) - Reps Bringdown : materiality scrape on MAE - and materiality - qualified reps, brought … Agreement) : - Reverse Merger: Closing conditions under the merger agreement must have been met - Reps: MAE - and materiality - qualified reps brought down
424B3
ORKA
Oruka Therapeutics Inc.
1 Aug 24
Prospectus supplement
4:10pm
of the representations and warranties of the other party, subject to the applicable materiality standard, and the performance in all material respects by the other party … and warranties of the other party, subject to the applicable materiality standard, and the performance in all material
respects by the other party of its
425
EX-10.2
h8tvyvd6t03i1ku
9 Jul 24
Business combination disclosure
5:04pm
8-K
EX-10.2
pab80mstbxw00m4799f
9 Jul 24
Entry into a Material Definitive Agreement
5:01pm
425
dmhqnbbgxvglchjntwa4
6 Jun 24
Business combination disclosure
4:45pm
425
9esojfqozlw4r16f8n
3 Apr 24
Business combination disclosure
7:33am
8-K
EX-2.1
zdymhvc0b3 m0n
3 Apr 24
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
7:31am
8-K
u5u1z ig942k97ex
3 Apr 24
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
7:31am
8-K
EX-99.2
2a4kkp6m1xj4pk
3 Apr 24
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
7:31am
8-K
EX-10.2
93l4dnurdoh0
3 Apr 24
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
7:31am
8-K
EX-10.1
9a9w2c7krsnl4egwqi
22 Jul 20
Entry into a Material Definitive Agreement
4:10pm